Accessibility Menu
Translational Development Acquisition Corp. logo

Translational Development Acquisition Corp.(NASDAQ) TDACW

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2025)+910%
5 YearN/A
1 Year+722%
1 Month+59%
$1.99
+12.43%
+0.22Today
Translational Development Acquisition Corp. last closing stock price
MetricPriceDate
Last closeUSD 2.022026-07-27
Translational Development Acquisition Corp. stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+18.82%USD 1.702026-07-20
1 month+59.06%USD 1.272026-06-26
3 month+1,920%USD 0.102026-04-28
Year to date+551.61%USD 0.312025-12-30
1 year+721.81%USD 0.252025-07-25
Since inception+910%USD 0.202025-02-13

Translational Development Acquisition Corp. Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

$6.21M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

0.93 (Low)

Price

$1.99

Volume

32,534

Open

$2.00

Previous Close

$2.02

Daily Range

$1.70 - $2.42

52-Week Range

$0.06 - $2.80

Estimated Earnings Date

N/A

TDACW News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Translational Development Acquisition Corp.

Translational Development Acquisition Corp. is a financial services company established in 2022 and headquartered in New York, New York. The company currently has no significant business operations and aims to finalize a strategic business combination with one or more entities.

Products and Services
  • Focus on strategic business combinations
  • Potential mergers and acquisitions
  • Asset acquisitions and reorganizations
Growth Outlook
  • Market capitalization stands at approximately $271.9 million
  • Recent quarterly net income of $1.33 million indicates potential profitability
  • Cash and short-term investments total $24,630, providing operational flexibility
Financial Highlights
  • Trailing twelve months (TTM) P/E ratio of 37.19 suggests growth expectations
  • Quarterly net income increased from $1.48 million to $1.33 million
  • Current ratio of 0.09 indicates a focus on managing short-term liabilities
Translational Development Acquisition Corp. operates in the shell company sector, primarily focusing on identifying and executing strategic business combinations. The company has a market capitalization of approximately $271.9 million, reflecting investor interest in its future potential. Recent financial performance shows a quarterly net income of $1.33 million, which is a positive indicator of profitability, despite the company not generating revenue from operations. The company's cash and short-term investments amount to $24,630, providing a cushion for operational needs as it seeks to finalize a business combination. The trailing twelve months P/E ratio of 37.19 suggests that investors are anticipating growth, which could be realized through successful mergers or acquisitions. Overall, Translational Development Acquisition Corp. presents an intriguing opportunity for investors interested in the financial services sector, particularly in the context of strategic business combinations. The company's focus on potential mergers and acquisitions positions it well for future growth, making it a noteworthy entity in the market.
AI Generated • Jul 13, 2026

Industry

Capital Markets

Headquarters

New York City, NY 10028, US

TDACW Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

3.57%

Return on Capital

-0.54%

Return on Assets

3.39%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

29.69%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

0

Volume

32.53K

Avg. Volume

81.87K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$878.29K

EBITDA

-$878.29K

Operating Cash Flow

-$681.97K

Capital Expenditure

-$3.00

Free Cash Flow

-$681.97K

Cash & ST Invst.

$24.63K

Total Debt

$500.00K

Translational Development Acquisition Corp. Performance Analysis

Translational Development Acquisition Corp. sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Translational Development Acquisition Corp. sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-80.0%
Q32025-09-308.0%
Q42025-12-31-9.0%
Q12026-03-31-16.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

2

N/A

Net Income

$1.33M

-10.1%

EBITDA

-$281.16K

+19.1%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$24.63K

-88.1%

Total Debt

$500.00K

-92.0%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$500.00K

-92.0%

Return on Assets

3.39%

N/A

Return on Invested Capital

-0.48%

N/A

Free Cash Flow

-$305.16K

-31.8%

Operating Cash Flow

-$305.16K

-31.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,396.49-0.00%
^DJIDJI
$52,083.00+0.00%
^IXICNASDAQ
$24,847.16-0.01%
BTCBitcoin
$64,796.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$91.67-0.01%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.25+0.10%
AALAmerican Airlines Group
$14.95+0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.24-0.02%

Questions About TDACW

What is the current price of Translational Development Acquisition Corp.?

Translational Development Acquisition Corp. is trading at $2.02 per share.

What is the 52-week range for Translational Development Acquisition Corp.?

Over the past 52 weeks, Translational Development Acquisition Corp. has traded between $0.06 and $2.80.

How much debt does Translational Development Acquisition Corp. have?

Translational Development Acquisition Corp. total debt is unavailable.

How much cash does Translational Development Acquisition Corp. have on hand?

Translational Development Acquisition Corp. does not have cash on hand data available.

What is Translational Development Acquisition Corp.’s dividend yield?

Translational Development Acquisition Corp. does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.